羟基法舒地尔
羟基法舒地尔 性质
| 储存条件 | Sealed in dry,Store in freezer, under -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| InChI | InChI=1S/C14H17N3O3S/c18-14-12-3-1-4-13(11(12)5-7-16-14)21(19,20)17-9-2-6-15-8-10-17/h1,3-5,7,15H,2,6,8-10H2,(H,16,18) |
| InChIKey | ZAVGJDAFCZAWSZ-UHFFFAOYSA-N |
| SMILES | C1(=O)C2=C(C(S(N3CCCNCC3)(=O)=O)=CC=C2)C=CN1 |
羟基法舒地尔 用途与合成方法
|
ROCK2 0.72 μM (IC 50 ) |
ROCK1 0.73 μM (IC 50 ) |
PKA 37 μM (IC 50 ) |
Hydroxyfasudil is a ROCK inhibitor, with IC 50 s of 0.73 and 0.72 μM for ROCK1 and ROCK2, respectively. Hydroxyfasudil also less potently inhibits PKA, with an IC 50 of 37 μM, 50-fold higher than those of the ROCKs. Hydroxyfasudil increases eNOS mRNA levels, with an EC 50 value of 0.8 ± 0.3 μM. Hydroxyfasudil (0-100 μM) concentration-dependently increases eNOS activity and stimulates NO production in human aortic endothelial cells (HAEC). Hydroxyfasudil (10 μM) increases the half-life of eNOS mRNA from 13 to 16 hours, but does not affect eNOS promoter activity at concentrations from 0.1 to 100 μM.
Hydroxyfasudil (10 mg/kg, i.p.) significantly increases both the average and maximal voided volumes in SD rats. Hydroxyfasudil also significantly decreases the maximal detrusor pressure. Hydroxyfasudil (3 mg/kg, i.p) inhibits hypercontractility induced by norepinephrine in spontaneously hypertensive rats (SHRs). Furthermore, Hydroxyfasudil (3, 10 mg/kg, i.p) significantly ameliorates decreased penile cGMP contents in rats.
羟基法舒地尔 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-13911 | 羟基法舒地尔 | 105628-72-6 | 1 mg | 155 |
| 2026-09-15 | HY-13911 | 羟基法舒地尔 | 105628-72-6 | 5 mg | 390 |
